To request Mental Health
Services or to access Mental
Health Crisis Services Call:

Medical Disorders
Basic InformationLookupsLatest News
Pfizer Says Lower Dose of Its COVID Vaccine Protects Younger ChildrenDeadly Liver Disease Tied to Obesity Is on the RiseCDC Signs Off on Moderna, J&J Boosters, Backs Mix n' Match ShotsMoving Monoclonal Antibody Treatments for COVID From Hospital to HomeConfusion, Seizures: People Hospitalized After Taking Veterinary Drug for COVIDMandates, Not Recommendations, Work Best to Get Folks Vaccinated: StudyPfizer Vaccine Booster Restores Nearly Full Protection, Company SaysTen Years On, Gene Therapy Still Beating Most Cases of 'Bubble Boy' Immune DiseaseSex of Fetus May Matter When COVID Strikes in PregnancyU.S. Has Shared 200 Million Shots With Other CountriesSalmonella Outbreak in 37 States Linked to Imported OnionsFDA Approves Moderna, J&J Booster Shots, Backs Mix n' Match VaccinesWhite House Announces COVID Vaccination Plan for Young KidsEven With Mild COVID, Obesity May Mean Worse SymptomsNew Device Might Spot 'Lazy Eye' in Kids EarlierA High-Tech Pointer to Pollutants That Trigger Asthma in KidsFlu Cases Already Up 23% This Season: WalgreensDoctors Report That Kidney Grown in Pig Worked in a HumanHeartburn Meds Might Be Good for Your GumsOne Big Factor for Survival After Spinal Cord Injury: ResilienceDying Young From Heart Disease: Where You Live in the U.S. MattersFDA Expected to Allow Mix n' Match COVID VaccinesPowell's COVID Death Despite Vaccination Shows Danger to Those With Weakened Immune SystemsAHA News: Your Next Doctor's Prescription Might Be to Spend Time in NatureOut-of-Pocket Medical Bills for COVID-19 May Average $3,800 in 2021: StudyLegionnaires' Disease Outbreak Hits Long Island, N.Y.State Lotteries Didn't Help Boost Vaccination RatesFDA Panel Recommends Approval of Johnson & Johnson Booster ShotHeart Defibs in Schools Are Saving Staff Lives: StudyHorseback Riding Carries Big Risk for Serious Injury: StudyTwo-Thirds of Parents of Kids Ages 5-11 Plan to Get Them Vaccinated Against COVID: PollAnother Study Finds Pfizer, Moderna Shots Effective Against COVID VariantsLyme Disease Often Spotted at Later Stage in Black PatientsFDA Panel Supports Moderna Booster Shot for Older Adults, People at High RiskIs a Really Bad Flu Season on the Way?Climate Change Could Bring Rising Obesity RatesKids Can Carry High, Infectious Levels of COVID CoronavirusMore Than Half of COVID-19 Survivors Will Get 'Long COVID'One-Third of Americans With Arthritis Get No ExerciseDeath Threats, Trolling Common for Scientists Who Speak to Media About COVIDAHA News: The Differences and Similarities Between the Flu and COVID-19FDA Questions Strength of Johnson & Johnson's Booster Shot DataHelmets Can Saves Lives in ATV, Dirt Bike CrashesCancer Care Costs U.S. $156 Billion Per Year; Drugs a Major FactorFDA Expert Panel to Weigh Approval of Moderna, Johnson & Johnson Booster ShotsAnti-Nausea Drug May Boost Survival for Some Cancer PatientsExpert Panel Backs Off Recommendation for Aspirin to Prevent Heart TroubleAccess to Top Drugs Makes the Difference for Black Lung Cancer PatientsRisk of COVID from Grocery Store Surfaces Very Low: Study60% of Americans Will Delay or Skip Flu Shot This Year: Survey
Questions and AnswersLinksBook Reviews
Related Topics

Men's Health
Women's Health

Trials Show COVID Vaccines Well Worth It for Cancer Patients

HealthDay News
by By Dennis Thompson HealthDay Reporter
Updated: Sep 24th 2021

new article illustration

FRIDAY, Sept. 24, 2021 (HealthDay News) -- If you have cancer and you think coronavirus vaccines may do you little good, don't let your hesitation stop you from getting the shots: A pair of clinical trials finds that patients' immune systems ramped up after vaccination.

The findings were presented this week during a virtual meeting of the European Society for Medical Oncology (ESMO Congress 2021).

"We have to vaccinate all of our cancer patients, and we can assure them that the vaccine is very active, regardless of the kind of [cancer] treatment" they receive, ESMO spokesman Dr. Antonio Passaro said in a HealthDay Now interview.

The first COVID vaccine trials excluded cancer patients. So, it has been an open question whether the shots could protect people undergoing chemotherapy or immunotherapy, he explained.

But two European trials -- VOICE and CAPTURE -- have now shown that the vaccines do indeed protect patients from COVID infection, said Passaro, a lung cancer expert at the European Institute of Oncology in Milan, Italy.

The VOICE study involved nearly 800 patients in the Netherlands. It included people with and without cancer, as well as folks who were being treated with chemotherapy, immunotherapy or a combination of the two. They received Moderna's two-dose mRNA vaccine.

About a month after their second vaccine dose, researchers found adequate levels of antibodies in 84% of patients on chemo; 93% of those on immunotherapy, and 89% of those who got combo chemo/immunotherapy.

Passaro said the results compare favorably to the high level of antibody response seen in more than 99% of the trial participants who didn't have cancer.

"The high rates of efficacy of the vaccine observed across the trial population, regardless of the type of anti-cancer treatment, constitute a strong and reassuring message for patients and their doctors," Passaro said in a meeting news release.

The trial also found that two doses are needed to achieve strong immunity in cancer patients. Only 1 in 3 chemo or chemo/immunotherapy patients achieved a sufficient response after their first shot -- about half as many as in those who were cancer-free.

The CAPTURE trial involved nearly 600 cancer patients in the United Kingdom. They received two doses of either the Pfizer-BioNTech or the AstraZeneca vaccine.

About one-third had previously contracted COVID-19, and the vaccine produced higher levels of virus-neutralizing antibodies in those patients.

To hear more about the trials, watch the HealthDay Now interview:

Passaro said these results support the notion that cancer patients and other immune-compromised people need to get the full vaccine regimen, and might even need a booster dose for best results.

He pointed to another clinical trial among about 230 cancer patients in Israel. Of those, fewer than a third developed antibodies after their first dose of the Pfizer vaccine. When they got their second dose, nearly 9 in 10 achieved an adequate immune response.

"The results confirm that for our patients, we need a full vaccination," Passaro said. "All of our cancer patients should be vaccinated for COVID-19, regardless of the kind of vaccine."

Findings presented at medical meetings are considered preliminary until published in a peer-reviewed journal.

More information

The American Cancer Society has more about COVID vaccines and cancer.

SOURCES: Antonio Passaro, MD, PhD, lung cancer expert, European Institute of Oncology, Milan, Italy; ESMO Congress 2021, virtual meeting, Sept. 16-21, 2021